Evaluation of nanoparticle albumin-bound paclitaxel loaded macrophages for glioblastoma treatment based on a microfluidic chip

被引:4
作者
Xie, Zuorun [1 ]
Ye, Junyi [1 ]
Gao, Xinghua [2 ]
Chen, Hang [3 ]
Chen, Maosong [1 ]
Lian, Jiangfang [3 ]
Ma, Jingyun [3 ]
Wang, Hongcai [1 ]
机构
[1] Ningbo Univ, Affiliated Lihuili Hosp, Dept Neurosurg, Ningbo, Zhejiang, Peoples R China
[2] Shanghai Univ, Mat Genome Inst, Shanghai, Peoples R China
[3] Ningbo Univ, Affiliated Lihuili Hosp, Ningbo Inst Innovat Combined Med & Engn, Ningbo, Zhejiang, Peoples R China
关键词
microfluidic chip; glioblastoma; macrophage-based carrier; drug delivery; nanoparticle albumin-bound paclitaxel; DELIVERY; GLIOMA;
D O I
10.3389/fbioe.2024.1361682
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Introduction: Glioblastoma (GBM) is a primary brain malignancy with a dismal prognosis and remains incurable at present. In this study, macrophages (M phi) were developed to carry nanoparticle albumin-bound paclitaxel (nab-PTX) to form nab-PTX/M phi. The aim of this study is to use a GBM-on-a-chip to evaluate the anti-GBM effects of nab-PTX/M phi.Methods: In this study, we constructed nab-PTX/M phi by incubating live M phi with nab-PTX. We developed a microfluidic chip to co-culture GBM cells and human umbilical vein endothelial cells, mimicking the simplified blood-brain barrier and GBM. Using a syringe pump, we perform sustainable perfusion of nutrient media. To evaluate the anti-GBM effects nab-PTX/M phi, we treated the GBM-on-a-chip model with nab-PTX/M phi and investigated GBM cell proliferation, migration, and spheroid formation.Results: At the chosen concentration, nab-PTX did not significantly affect the viability, chemotaxis and migration of M phi. The uptake of nab-PTX by M phi occurred within 1 h of incubation and almost reached saturation at 6 h. Additionally, nab-PTX/M phi exhibited the M1 phenotype, which inhibits tumor progression. Following phagocytosis, M phi were able to release nab-PTX, and the release of nab-PTX by M phi had nearly reached its limit at 48 h. Compared with control group and blank M phi group, individual nab-PTX group and nab-PTX/M phi group could inhibit tumor proliferation, invasion and spheroid formation. Meanwhile, the anti-GBM effect of nab-PTX/M phi was more significant than nab-PTX.Discussion: Our findings demonstrate that nab-PTX/M phi has a significant anti-GBM effect compared to individual nab-PTX or M phi administration, suggesting M phi as potential drug delivery vectors for GBM therapy. Furthermore, the developed GBM-on-a-chip model provides a potential ex vivo platform for innovative cell-based therapies and tailored therapeutic strategies for GBM.
引用
收藏
页数:15
相关论文
共 50 条
[21]   Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells [J].
Vallo, Stefan ;
Koepp, Raoul ;
Michaelis, Martin ;
Rothweiler, Florian ;
Bartsch, Georg ;
Brandt, Maximilian P. ;
Gust, Kilian M. ;
Wezel, Felix ;
Blaheta, Roman A. ;
Haferkamp, Axel ;
Cinatl, Jindrich, Jr. .
ONCOLOGY LETTERS, 2017, 13 (06) :4085-4092
[22]   Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer [J].
Shi, Wenjie ;
Wan, Xinyu ;
Wang, Ye ;
He, Jinzhi ;
Huang, Xiaofeng ;
Xu, Yinggang ;
Zhang, Weiwei ;
Chen, Rui ;
Wang, Lexin ;
Zheng, Ran ;
Ma, Lingjun ;
Li, Xuan ;
Xu, Lu ;
Zha, Xiaoming ;
Wang, Jue .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2023, 49
[23]   Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer [J].
Yoshida, Hironori ;
Kim, Young Hak ;
Ozasa, Hiroaki ;
Nagai, Hiroki ;
Sakamori, Yuichi ;
Nakaoku, Takashi ;
Yagi, Yoshitaka ;
Tsuji, Takahiro ;
Nomizo, Takashi ;
Mishima, Michiaki .
MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (01) :213-215
[24]   Layer-by-layer assembly of hierarchical nanoarchitectures to enhance the systemic performance of nanoparticle albumin-bound paclitaxel [J].
Ruttala, Hima Bindu ;
Ramasamy, Thiruganesh ;
Shin, Beom Soo ;
Choi, Han-Gon ;
Yong, Chul Soon ;
Kim, Jong Oh .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 519 (1-2) :11-21
[25]   Nanoparticle Albumin-Bound Paclitaxel and Solvent-Based Paclitaxel as Chemotherapy Options for Patients With Advanced Gastric Cancer: A Systematic Review and Meta-Analysis [J].
Gangannapalle, Mahesh ;
Shahnoor, Husna ;
Sattar, Lubna ;
Nagi, Talwinder K. ;
Al-Tekreeti, Marwah ;
Khan, Muhammad Waqas ;
Haseeb, Madiha D. ;
Khan, Areeba .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (07)
[26]   Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer [J].
Yang, Miaomiao ;
Qu, Huajun ;
Liu, Aina ;
Liu, Jiannan ;
Sun, Ping ;
Li, Hua .
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2019, 15 (07) :1561-1566
[27]   Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer [J].
Kinoshita, Ryo ;
Ishima, Yu ;
Chuang, Victor T. G. ;
Nakamura, Hideaki ;
Fang, Jun ;
Watanabe, Hiroshi ;
Shimizu, Taro ;
Okuhira, Keiichiro ;
Ishida, Tatsuhiro ;
Maeda, Hiroshi ;
Otagiri, Masaki ;
Maruyama, Toru .
BIOMATERIALS, 2017, 140 :162-169
[28]   Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer [J].
Mei, Yu ;
Shi, Min ;
Zhu, Zhenglun ;
Yuan, Hong ;
Yan, Chao ;
Li, Chen ;
Feng, Tienan ;
Yan, Min ;
Zhang, Jun ;
Zhu, Zhenggang .
FUTURE ONCOLOGY, 2021, 18 (02) :139-148
[29]   Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study [J].
Tian, Zhichao ;
Dong, Shuping ;
Yang, Yang ;
Gao, Shilei ;
Yang, Yonghao ;
Yang, Jinpo ;
Zhang, Peng ;
Wang, Xin ;
Yao, Weitao .
BMC CANCER, 2022, 22 (01)
[30]   Nanoparticle Albumin-Bound Paclitaxel- and/or Gemcitabine-Induced Scleroderma Accompanied by Acanthosis Nigricans-Like Skin Changes [J].
Motegi, Sei-ichiro ;
Ishikawa, Mai ;
Sekiguchi, Akiko ;
Ishikawa, Osamu .
CASE REPORTS IN DERMATOLOGY, 2019, 11 (03) :273-277